Europe CRISPR Market Forecast 2019-2027

Europe CRISPR Market Forecast 2019-2027

  • December 2018 •
  • 99 pages •
  • Report ID: 4595253 •
  • Format: PDF
KEY FINDINGS
Clustered regularly interspaced short palindrome repeats (CRISPR) are fragments of prokaryotic DNA containing short redundancies of base sequences. The European market for CRISPR is anticipated to evolve with 30.98% CAGR over the forecast period of 2019-2027.

MARKET INSIGHTS
U.K market dominated the Europe CRISPR market in 2018 and is expected to continue its dominance throughout the forecast period. Growing stem cell research in the region is significantly aiding the market growth. Germany implies strict liability for contamination with GMOs, and has tough, strict and methodically enforced regulations over the release of GMOs into the market. On the other hand, the law on Biomedical Research in Spain allows research on embryos, but for therapeutic purposes only. In France, some laws like the Law on Bioethics 2004 and 2011 restricts the use of human embryos and embryonic stem cells for research until proper regulatory conditions are met.

COMPETITIVE INSIGHTS
Companies like Novartis International Ag, New England Biolabs Inc, Lonza Group Ag, Precision Biosciences, Sigma-Aldrich (Merck), Thermo Fisher Scientific, Sangamo Biosciences Inc, Integrated DNA Technologies (IDT), Cellectis Bioresearch Sas, Horizon Discovery Plc, and Editas Medicine have strongly established themselves in this market.

Companies mentioned
1. ADDGENE
2. APPLIED STEMCELL, INC.
3. CARIBOU BIOSCIENCES INC.
4. CELLECTIS BIORESEARCH SAS
5. CRISPR THERAPEUTICS AG
6. DIACARTA, INC.
7. EDIGENE, INC.
8. EDITAS MEDICINE
9. GENECOPOEIA, INC.
10. GENEDATA AG
11. GENSCRIPT
12. HORIZON DISCOVERY PLC
13. INTEGRATED DNA TECHNOLOGIES
14. INTELLIA THERAPEUTICS INC.
15. LONZA GROUP AG
16. NEW ENGLAND BIOLABS INC.
17. NOVARTIS INTERNATIONAL AG
18. ORIGENE TECHNOLOGIES INC.
19. PRECISION BIOSCIENCES
20. SANGAMO THERAPEUTICS
21. SIGMA-ALDRICH (MERCK)
22. THERMO FISHER SCIENTIFIC
23. TRANSPOSAGEN BIOPHARMACEUTICALS INC.